{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:34Z","timestamp":1790614894450,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.annder.2020.02.010","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T07:48:09Z","timestamp":1585900089000},"page":"475-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Avanc\u00e9es dans la compr\u00e9hension de la physiopathologie de la n\u00e9crolyse \u00e9pidermique (syndrome de Stevens-Johnson et n\u00e9crolyse \u00e9pidermique toxique)"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0262-2754","authenticated-orcid":false,"given":"S.","family":"Lalev\u00e9e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Contassot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3762-4605","authenticated-orcid":false,"given":"O.","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ben Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vocanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"De Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-7346","authenticated-orcid":false,"given":"S.","family":"Hue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7096","authenticated-orcid":false,"given":"S.","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2020.02.010_bib0315","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2020.02.010_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335612","article-title":"Epidemiology of cutaneous adverse drug reactions","volume":"97","author":"Mockenhaupt","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.annder.2020.02.010_bib0325","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.18424","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate","volume":"182","author":"Chaby","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0330","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jaad.2013.12.025","article-title":"HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4+ T cells","volume":"70","author":"Yang","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0335","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0340","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0345","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0355","article-title":"Health-related quality of life and long-term sequelae in epidermal necrolysis survivors: an observational study of 57\u00a0patients","author":"Ingen-Housz-Oro","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0360","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjd.18023","article-title":"Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae","volume":"181","author":"Hajj","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0365","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bjd.17267","article-title":"Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31\u00a0patients","volume":"180","author":"Hefez","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0370","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0375","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/infdis\/jit383","article-title":"Clinicopathologic analysis of coxsackievirus a6\u00a0new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions","volume":"208","author":"Chung","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2020.02.010_bib0380","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13023-018-0793-7","article-title":"Epidermal necrolysis French national diagnosis and care protocol (PNDS\u00a0; protocole national de diagnostic et de soins)","volume":"13","author":"Ingen-Housz-Oro","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.annder.2020.02.010_bib0385","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174\u00a0patients-exposed\/unexposed and propensity score-matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0390","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic Immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0395","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bjps.2016.01.034","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"69","author":"Creamer","year":"2016","journal-title":"J Plast Reconstr Aesthetic Surg"},{"key":"10.1016\/j.annder.2020.02.010_bib0400","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: Building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2020.02.010_bib0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.annpat.2017.10.015","article-title":"Histopathologie des r\u00e9actions cutan\u00e9es m\u00e9dicamenteuses","volume":"38","author":"Ortonne","year":"2018","journal-title":"Ann Pathol"},{"key":"10.1016\/j.annder.2020.02.010_bib0410","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1191\/0961203304lu2037sa","volume":"13","author":"Ting","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.annder.2020.02.010_bib0415","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaad.2018.03.013","article-title":"Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: a single-center series of 33\u00a0cases compared with 100\u00a0cases induced by other causes","volume":"79","author":"Amode","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0420","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamadermatol.2018.2120","article-title":"Association between severe acute contact dermatitis due to Nigella sativa oil and epidermal apoptosis","volume":"154","author":"Gaudin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0425","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: a French retrospective pharmacovigilance study of 69\u00a0cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.annder.2020.02.010_bib0430","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0435","first-page":"74","article-title":"New strategies to predict and prevent serious immunologically mediated adverse drug reactions","volume":"129","author":"Phillips","year":"2018","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.annder.2020.02.010_bib0440","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances","volume":"42","author":"Bell\u00f3n","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.annder.2020.02.010_bib0445","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/ACI.0b013e32832d565c","article-title":"Role of T cells in nonimmediate allergic drug reactions","volume":"9","author":"Rozieres","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0450","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0455","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2020.02.010_bib0460","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3\u00a0and hypersensitivity to HIV-1\u00a0reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2020.02.010_bib0465","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2020.02.010_bib0470","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.annder.2020.02.010_bib0475","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801\u00a0allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annder.2020.02.010_bib0480","doi-asserted-by":"crossref","first-page":"6431694","DOI":"10.1155\/2018\/6431694","article-title":"An updated review of the molecular mechanisms in drug hypersensitivity","volume":"2018","author":"Chen","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.annder.2020.02.010_bib0485","first-page":"CD010891","article-title":"Genetic testing for prevention of severe drug-induced skin rash","volume":"7","author":"Alfirevic","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annder.2020.02.010_bib0490","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2015.03.019","article-title":"Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01","volume":"136","author":"Sousa-Pinto","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0495","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jocn.2010.12.054","article-title":"Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions","volume":"18","author":"Locharernkul","year":"2011","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.annder.2020.02.010_bib0500","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2020.02.010_bib0505","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaci.2005.10.030","article-title":"Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions","volume":"117","author":"Beeler","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0510","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"HLAs: key regulators of T-cell-mediated drug hypersensitivity","volume":"91","author":"Redwood","year":"2018","journal-title":"HLA"},{"key":"10.1016\/j.annder.2020.02.010_bib0515","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/all.13765","article-title":"Immune pathomechanism and classification of drug hypersensitivity","volume":"74","author":"Pichler","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2020.02.010_bib0520","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0525","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41467-019-11396-2","article-title":"Identification of drug-specific public TCR driving severe cutaneous adverse reactions","volume":"10","author":"Pan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.annder.2020.02.010_bib0530","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaci.2006.07.013","article-title":"Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams","volume":"118","author":"Rodriguez-Pena","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0535","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jat.3033","article-title":"Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1\u00a0cells","volume":"35","author":"Gon\u00e7alo","year":"2015","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.annder.2020.02.010_bib0540","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2020.02.010_bib0545","doi-asserted-by":"crossref","first-page":"e0117160","DOI":"10.1371\/journal.pone.0117160","article-title":"Abacavir-reactive memory T cells are present in drug na\u00efve individuals","volume":"10","author":"Lucas","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.annder.2020.02.010_bib0550","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI99321","article-title":"A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity","volume":"128","author":"Cardone","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.annder.2020.02.010_bib0555","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0560","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.annder.2020.02.010_bib0565","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaci.2009.10.030","article-title":"CD94\/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"125","author":"Morel","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2020.02.010_bib0570","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15\u00a0Is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0575","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0580","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0585","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0625.2010.01176.x","article-title":"Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis","volume":"20","author":"de Araujo","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0590","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1\u00a0interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annder.2020.02.010_bib0595","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/jid.2015.159","article-title":"RIPping the Skin Apart: Necroptosis Signaling in Toxic Epidermal Necrolysis","volume":"135","author":"Panayotova-Dimitrova","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.01.006","article-title":"RIP3\u00a0as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis","author":"Hasegawa","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2020.02.010_bib0605","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.annder.2020.02.010_bib0610","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjd.17610","article-title":"Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1\u00a0protein in drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"181","author":"Carr","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.02.010_bib0615","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jaip.2018.05.037","article-title":"Differential expression of alarmins: IL-33\u00a0as a candidate marker for early diagnosis of toxic epidermal necrolysis","volume":"7","author":"Adachi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2020.02.010_bib0310","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/cea.13449","article-title":"Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns","volume":"49","author":"Lalev\u00e9e","year":"2019","journal-title":"Clin Exp Allergy"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820301496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820301496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:09:04Z","timestamp":1758971344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963820301496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":62,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0151963820301496"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2020.02.010","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avanc\u00e9es dans la compr\u00e9hension de la physiopathologie de la n\u00e9crolyse \u00e9pidermique (syndrome de Stevens-Johnson et n\u00e9crolyse \u00e9pidermique toxique)","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2020.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}